Date: 11 - 13 May 2015
Switzerland, October 27 -- The World Health Organization’s (WHO’s) Vector Control Advisory Group (VCAG) published its second annual VCAG report today which includes evaluation of the supporting evidence for Vestergaard’s product claim for PermaNet® 3.0. The report states that “The manufacturers have been very careful to make a relatively modest claim that can be supported by the combined evidence from multiple studies in many areas of pyrethroid resistance”.MalariaWorld Journal (MWJ) is the first truly Open Access, peer reviewed, journal with an exclusive focus on malaria –
MESA is very excited to be launching its new website and knowledge management tools at ASTMH in New Orleans on November 2nd!
Grants will support researchers in following up on Malaria Box open source data, available on ChEMBL.
The draft GMAP2 will be be available for you to read and feedback on later this year - but not on Oct 15th 2014.
The Second Global Malaria Action Plan (GMAP2) will cover the timeframe 2016-2025.
You are strongly encouraged to have a look and contribute by sharing your vision for a malaria-free world.
Clinical trials are not suitable to identify rare, potentially serious adverse effects of drugs, or to define their safety in high risk populations.
Artemisinin-based combination therapies (or ACTs) are considered safe, but there are concerns over their potential to cause damage to parts of the brain. There is also a concern about their safety in patients infected with HIV.
Dear Sir or Madam
The Pan African Mosquito Control Association (PAMCA) is a professional body comprised of mosquito control and research professionals from Africa and beyond. The overall objective of the organization is to promote control of and research on mosquitoes and to disseminate information on the bionomics of mosquitoes and related subjects across Africa and worldwide. PAMCA is organising its first Annual Conference in Nairobi from 6 to 8 October 2014 at Panari Hotel.
Follow the MESA blogs directly from Mexico here.
